Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Raises Outlook
Get Alerts BMY Hot Sheet
EPS Growth %: -21.5%
Financial Fact:
Earnings Before Income Taxes: 1.56B
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.69, $0.03 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.6 billion.
“During the second quarter we delivered strong sales and earnings growth, achieved important regulatory milestones with Opdivo across multiple types of cancer, and further advanced our leadership in Immuno-Oncology through the breadth of the clinical data we presented at ASCO,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “I am confident strong performance of our in-line products, progress with our diversified pipeline and our focused approach to business development position us well for continued success.”
GUIDANCE:
Bristol-Myers Squibb sees FY2016 EPS of $2.55-$2.65, versus the consensus of $2.60.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- Wipro (WIT) Tops Q1 EPS by 1c
- Growth isn't weak enough to truly undercut inflation pressures - BMO
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!